Human peripheral blood mononuclear cell proliferation (PBMC proliferation)

Human peripheral blood mononuclear cell (PBMC) proliferation is a fundamental biological process characterized by the rapid division of lymphocytes (T cells, B cells, and NK cells) and monocytes in response to antigenic or mitogenic stimulation (NCBI, 2023). This process is a hallmark of the adaptive immune response, facilitating the expansion of specific cell populations to combat pathogens or respond to inflammatory signals. In the context of drug discovery, PBMC proliferation is utilized as a phenotypic readout in functional assays to assess the immunomodulatory potential of candidate compounds (PubMed, 2011). While it is not a single molecular target, it represents the integrated outcome of multiple signaling pathways, including the T-cell receptor (TCR) and various cytokine receptors. Therapeutic intervention often aims to suppress this proliferation in conditions like organ transplant rejection and autoimmune diseases using drugs such as tacrolimus or mycophenolate mofetil (StatPearls, 2023). Conversely, enhancing PBMC proliferation is a strategy in cancer immunotherapy to bolster the body's natural defense against malignant cells.

Other names

PBMC proliferationLymphocyte proliferationImmune cell proliferationPeripheral blood mononuclear cell activation

Modulation of intracellular signaling cascades (e.g., calcineurin/NFAT, mTOR, JAK/STAT) and inhibition of nucleotide synthesis to prevent DNA replication and cell division in immune cells (StatPearls, 2023).